Taylor Hotz

Taylor Hotz has worked for a number of companies since 2010. From 2010-2015, Hotz was a Research Associate at the University of Colorado Boulder, where they conducted an Honor's Thesis on Multicolor Fluorescent Lineage Analysis of Satellite Cells and maintained tissue culture cell samples. From 2015-2020, Hotz was a Professional Research Assistant-Lab Manager at the University of Colorado Anschutz Medical Campus, where they determined whether small molecules targeting Eya2 phosphatase activity had efficacious effects in adult and pediatric cancers in vitro. Hotz then worked as a Senior Research Associate at Xilio Therapeutics, Inc. from 2020-2021, and then as a Research Associate III at the Broad Institute of MIT and Harvard from 2020-2022. In this role, Hotz carried out high throughput cancer screens utilizing thousands of compounds to treat up to 1000 pooled adherent and suspension human cancer cell lines that each have a unique DNA barcode. Hotz is currently a Principal Research Associate at Accent Therapeutics, Inc. since 2022, where they generate PARP-resistant HGSOC ovarian cancer cell lines to interrogate PARP efficacy in combination with FDA-approved Tazverik, develop and optimize a 21-day EX-LTP in vitro assay to screen efficacy of epigenetic inhibitors in multiple cancer indications, and support the medicinal chemistry team by developing and running 384-well proliferation HTS assays for SAR experiments of lead compounds.

Taylor Hotz graduated from the University of Colorado Boulder in 2014 with a Bachelor's degree in Integrative Physiology, Psychology (Double Major), and a Certificate in Neuroscience.